[go: up one dir, main page]

MX2016016296A - El control efectivo y eficaz del fosfato serico para una osificacion optima. - Google Patents

El control efectivo y eficaz del fosfato serico para una osificacion optima.

Info

Publication number
MX2016016296A
MX2016016296A MX2016016296A MX2016016296A MX2016016296A MX 2016016296 A MX2016016296 A MX 2016016296A MX 2016016296 A MX2016016296 A MX 2016016296A MX 2016016296 A MX2016016296 A MX 2016016296A MX 2016016296 A MX2016016296 A MX 2016016296A
Authority
MX
Mexico
Prior art keywords
effective
bone formation
efficient control
serum phosphate
optimal bone
Prior art date
Application number
MX2016016296A
Other languages
English (en)
Other versions
MX381052B (es
Inventor
Emil Kakkis
San Martin Javier
Sudo Tomohiro
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of MX2016016296A publication Critical patent/MX2016016296A/es
Publication of MX381052B publication Critical patent/MX381052B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención proporciona composiciones y métodos para tratar un trastorno hipofosfatémico, tal como hipofosfatemia ligada al cromosoma X (XLH); el método conlleva administrar a un sujeto una composición farmacéutica que contiene un ligando anti-FGF23, donde el régimen de dosificación del fármaco se diseña para alcanzar un control efectivo y eficaz de la actividad de FGF23.
MX2016016296A 2014-06-09 2015-05-29 El control efectivo y eficaz del fosfato serico para una osificacion optima. MX381052B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462009474P 2014-06-09 2014-06-09
PCT/US2015/033226 WO2015191312A1 (en) 2014-06-09 2015-05-29 The effective and efficient control of serum phosphate for optimal bone formation

Publications (2)

Publication Number Publication Date
MX2016016296A true MX2016016296A (es) 2017-10-12
MX381052B MX381052B (es) 2025-03-12

Family

ID=54769049

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016016296A MX381052B (es) 2014-06-09 2015-05-29 El control efectivo y eficaz del fosfato serico para una osificacion optima.
MX2021003740A MX2021003740A (es) 2014-06-09 2016-12-08 El control efectivo y eficaz del fosfato serico para una osificacion optima.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003740A MX2021003740A (es) 2014-06-09 2016-12-08 El control efectivo y eficaz del fosfato serico para una osificacion optima.

Country Status (25)

Country Link
US (4) US10639360B2 (es)
EP (3) EP4647444A3 (es)
JP (2) JP6808493B2 (es)
KR (3) KR20210099180A (es)
CN (1) CN106604743A (es)
AR (2) AR100689A1 (es)
AU (1) AU2015275128C1 (es)
BR (2) BR112016028567A2 (es)
CA (1) CA2949234C (es)
CL (1) CL2016003179A1 (es)
CY (1) CY1124328T1 (es)
DK (2) DK3845245T3 (es)
ES (2) ES3040805T3 (es)
FI (1) FI3845245T3 (es)
HR (2) HRP20251099T1 (es)
HU (2) HUE053271T2 (es)
LT (2) LT3845245T (es)
MX (2) MX381052B (es)
PE (1) PE20170248A1 (es)
PL (2) PL3151859T3 (es)
PT (2) PT3151859T (es)
RS (2) RS61443B1 (es)
SI (2) SI3845245T1 (es)
SM (2) SMT202100096T1 (es)
WO (1) WO2015191312A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3404102T (pt) 2004-04-21 2021-09-16 Alexion Pharma Inc Conjugados de entrega óssea e método de usar os mesmos para direcionar as proteínas ao osso
LT3845245T (lt) 2014-06-09 2025-09-25 Ultragenyx Pharmaceutical Inc. Veiksminga ir efektyvi serumo fosfatų kontrolė, skirta optimalaus kaulų formavimosi užtikrinimui
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CN107405390A (zh) 2014-12-05 2017-11-28 阿雷克森制药公司 用重组碱性磷酸酶治疗癫痫
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
CN106709662B (zh) * 2016-12-30 2021-07-02 山东鲁能软件技术有限公司 一种电力设备运行工况划分方法
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
ES2972119T3 (es) 2018-08-10 2024-06-11 Alexion Pharma Inc Cicatrización ósea en implantes utilizando fosfatasa alcalina
EP3946593A1 (en) * 2019-03-29 2022-02-09 Atarga, LLC Anti fgf23 antibody
JP7796645B2 (ja) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
AU2024237816A1 (en) * 2023-03-10 2025-09-18 Ultragenyx Pharmaceutical Inc. Human fgf23-binding antibodies with improved affinity and efficacy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
AU2005202100A1 (en) 1999-05-11 2005-06-09 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
KR20090036151A (ko) * 2000-07-19 2009-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법
CN101275136A (zh) 2000-08-11 2008-10-01 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
JP4527982B2 (ja) 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
US8158725B2 (en) 2005-08-22 2012-04-17 Bridgestone Corporation Functionalized polymers and tires therefrom
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
LT3845245T (lt) 2014-06-09 2025-09-25 Ultragenyx Pharmaceutical Inc. Veiksminga ir efektyvi serumo fosfatų kontrolė, skirta optimalaus kaulų formavimosi užtikrinimui

Also Published As

Publication number Publication date
US20200330575A1 (en) 2020-10-22
SMT202100096T1 (it) 2021-03-15
CY1124328T1 (el) 2022-07-22
US12358976B2 (en) 2025-07-15
JP6808493B2 (ja) 2021-01-06
EP3151859A4 (en) 2018-01-17
US10639360B2 (en) 2020-05-05
MX381052B (es) 2025-03-12
LT3151859T (lt) 2021-03-25
CA2949234C (en) 2022-03-22
AU2015275128B2 (en) 2019-10-31
ES2851674T3 (es) 2021-09-08
MX2021003740A (es) 2021-05-27
EP3151859B1 (en) 2020-11-25
WO2015191312A1 (en) 2015-12-17
SI3845245T1 (sl) 2025-10-30
PL3151859T3 (pl) 2021-07-26
CN106604743A (zh) 2017-04-26
HRP20251099T1 (hr) 2025-11-07
KR20170013993A (ko) 2017-02-07
RS61443B1 (sr) 2021-03-31
AR100689A1 (es) 2016-10-26
EP3845245A1 (en) 2021-07-07
EP3845245B1 (en) 2025-06-25
KR20240093956A (ko) 2024-06-24
HUE073105T2 (hu) 2025-12-28
EP4647444A2 (en) 2025-11-12
BR112016028567A2 (pt) 2018-01-30
PT3151859T (pt) 2021-02-03
BR122023023102A2 (pt) 2024-03-05
LT3845245T (lt) 2025-09-25
EP4647444A3 (en) 2026-01-21
SMT202500342T1 (it) 2025-11-10
AR131056A2 (es) 2025-02-12
PE20170248A1 (es) 2017-04-14
FI3845245T3 (fi) 2025-09-09
US11202822B2 (en) 2021-12-21
CA2949234A1 (en) 2015-12-17
EP3151859A1 (en) 2017-04-12
US20220133871A1 (en) 2022-05-05
DK3845245T3 (da) 2025-09-15
JP6993490B2 (ja) 2022-02-03
PT3845245T (pt) 2025-09-16
RS67294B1 (sr) 2025-11-28
ES3040805T3 (en) 2025-11-05
HRP20210250T1 (hr) 2021-04-02
KR20210099180A (ko) 2021-08-11
AU2015275128A1 (en) 2016-12-08
CL2016003179A1 (es) 2017-11-03
PL3845245T3 (pl) 2025-12-22
US20150353633A1 (en) 2015-12-10
SI3151859T1 (sl) 2021-06-30
AU2015275128C1 (en) 2020-02-13
US20240115683A1 (en) 2024-04-11
JP2021050226A (ja) 2021-04-01
DK3151859T3 (da) 2021-02-15
HUE053271T2 (hu) 2021-06-28
US11771748B2 (en) 2023-10-03
JP2017524656A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2016016296A (es) El control efectivo y eficaz del fosfato serico para una osificacion optima.
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PE20150887A1 (es) Compuestos de benceno sustituidos
BR112017021021A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112017011536A2 (pt) terapias de combinação
AR091220A1 (es) Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX384490B (es) Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias.
MX373283B (es) Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento.
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
CR20170085A (es) Terapia adjuntiva con 25-hidroxi vitamina d
CR20160433A (es) Nuevos compuestos
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
NI201700066A (es) Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson